Merck KGaA (MKKGY)
(Delayed Data from OTC)
$24.84 USD
-0.52 (-2.03%)
Updated Sep 25, 2025 03:59 PM ET
4-Sell of 5 4
A Value D Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Merck KGaA has a PEG ratio of 2.53 compared to the Medical - Drugs industry's PEG ratio of 1.33.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MKKGY 24.84 -0.52(-2.03%)
Will MKKGY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MKKGY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MKKGY
MKKGY or STVN: Which Is the Better Value Stock Right Now?
Merck KGaA (MKKGY) Upgraded to Strong Buy: Here's Why
MKKGY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should Value Investors Buy Merck KGaA (MKKGY) Stock?
MKKGY vs. ZTS: Which Stock Is the Better Value Option?
Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?
Other News for MKKGY
HHS sends proposed drug pricing rule to White House for review
mRNA Biotechs - Long-Term Value Risks Abound
Merck KGaA price target lowered by EUR 10 at Morgan Stanley
Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data
Columbia Pyrford International Stock Fund Q2 2025 Commentary